- Home
- OKLO vs ACAD Comparison
OKLO vs ACAD Comparison
Compare OKLO & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKLO
- ACAD
- Stock Information
- Founded
- OKLO 2013
- ACAD 1993
- Country
- OKLO United States
- ACAD United States
- Employees
- OKLO N/A
- ACAD N/A
- Industry
- OKLO
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- OKLO
- ACAD Health Care
- Exchange
- OKLO NYSE
- ACAD Nasdaq
- Market Cap
- OKLO 3.1B
- ACAD 2.5B
- IPO Year
- OKLO N/A
- ACAD 2004
- Fundamental
- Price
- OKLO $28.11
- ACAD $17.44
- Analyst Decision
- OKLO Buy
- ACAD Buy
- Analyst Count
- OKLO 6
- ACAD 15
- Target Price
- OKLO $46.40
- ACAD $24.21
- AVG Volume (30 Days)
- OKLO 9.7M
- ACAD 1.7M
- Earning Date
- OKLO 05-13-2025
- ACAD 05-07-2025
- Dividend Yield
- OKLO N/A
- ACAD N/A
- EPS Growth
- OKLO N/A
- ACAD N/A
- EPS
- OKLO N/A
- ACAD 1.37
- Revenue
- OKLO N/A
- ACAD $996,283,000.00
- Revenue This Year
- OKLO N/A
- ACAD $13.07
- Revenue Next Year
- OKLO N/A
- ACAD $10.06
- P/E Ratio
- OKLO N/A
- ACAD $12.73
- Revenue Growth
- OKLO N/A
- ACAD 22.42
- 52 Week Low
- OKLO $5.35
- ACAD $13.40
- 52 Week High
- OKLO $59.14
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- OKLO 58.45
- ACAD 67.70
- Support Level
- OKLO $24.53
- ACAD $14.45
- Resistance Level
- OKLO $28.97
- ACAD $15.31
- Average True Range (ATR)
- OKLO 1.91
- ACAD 0.69
- MACD
- OKLO 0.70
- ACAD 0.37
- Stochastic Oscillator
- OKLO 89.74
- ACAD 94.92
About OKLO OKLO INC
Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.